Literature DB >> 15507670

Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?

José María Sayagués1, María Dolores Tabernero, Angel Maíllo, Ana Espinosa, Ana Rasillo, Pedro Díaz, Juana Ciudad, Antonio López, Marta Merino, Jesús María Gonçalves, Angel Santos-Briz, Francisco Morales, Alberto Orfao.   

Abstract

Meningiomas are cytogenetically heterogeneous tumors in which chromosome gains and losses frequently occur. Based on the intertumoral cytogenetic heterogeneity of meningiomas, hypothetical models of clonal evolution have been proposed in these tumors which have never been confirmed at the intratumoral cell level. The aim of this study was to establish the intratumoral patterns of clonal evolution associated with chromosomal instability in individual patients as a way to establish tumor progression pathways in meningiomas and their relationship with tumor histopathology and behavior. A total of 125 meningioma patients were analyzed at diagnosis. In all cases, multicolor interphase fluorescence in situ hybridization (iFISH) studies were performed on fresh tumor samples for the detection of quantitative abnormalities for 11 different chromosomes. In addition, overall tumor cell DNA content was measured in parallel by flow cytometry. iFISH studies were also performed in parallel on tissue sections in a subset of 30 patients. FISH studies showed that 56 (45%) of the 125 cases analyzed had a single tumor cell clone, all these cases corresponding to histologically benign grade I tumors. In the remaining cases (55%) more than one tumor cell clone was identified: two in 45 cases (36%), three in 19 (15%), and four or more clones in five cases (4%). Overall, flow cytometric analysis of cell DNA contents showed the presence of DNA aneuploidy in 44 of these cases (35%), 30% corresponding to DNA hyperdiploid and 5% to hypodiploid cases; from the DNA aneuploid cases, 35 (28%) showed two clones and 9 (7%) had three or more clones. A high degree of correlation (r >/= 0.89; P < 0.001) was found between FISH and flow cytometry as regards the overall quantitative DNA changes detected with both techniques, the former being more sensitive. Among the cases with chromosome abnormalities, the earliest tumor cell clone observed was frequently characterized by the loss of one or more chromosomes (64% of all meningiomas); loss of either a single chromosome 22 or, less frequently, of a sex chromosome (X or Y) and del (1p) was commonly found as the single initial cytogenetic aberration (30%, 5%, and 5% of the cases, respectively). Interestingly, an isolated loss of chromosome 22 was only found as the initial abnormality in one out of 14 atypical/anaplastic meningiomas, while the same cytogenetic pattern was present in the ancestral tumor cell clone of 32% of the benign tumors. Cytogenetic patterns based on chromosome gains were found in the ancestral tumor cell clone in 4% of the patients, 2% corresponding to tetraploid tumors. Overall, cytogenetic evolution of the earliest tumor cell clones was frequently associated with tetraploidization (31%). Our results show that meningiomas are genetically heterogeneous tumors that display different patterns of numerical chromosome changes, with the presence of more than one tumor cell clone detected in almost half of the cases including all atypical/anaplastic cases. Interestingly, the pathways of intratumoral clonal evolution observed in the benign tumors were different from those observed in atypical/anaplastic meningiomas, suggesting that the latter tumors might not always represent a more advanced stage of histologically benign meningiomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507670      PMCID: PMC1867491          DOI: 10.1016/S1525-1578(10)60527-2

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  42 in total

1.  Genetic progression model for head and neck cancer: implications for field cancerization.

Authors:  J Califano; P van der Riet; W Westra; H Nawroz; G Clayman; S Piantadosi; R Corio; D Lee; B Greenberg; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  Role of genomic instability in meningioma progression.

Authors:  M Simon; A J Kokkino; R E Warnick; J M Tew; A von Deimling; A G Menon
Journal:  Genes Chromosomes Cancer       Date:  1996-08       Impact factor: 5.006

3.  Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas.

Authors:  R H Lekanne Deprez; P H Riegman; E van Drunen; U L Warringa; N A Groen; S Z Stefanko; J W Koper; C J Avezaat; P G Mulder; E C Zwarthoff
Journal:  J Neuropathol Exp Neurol       Date:  1995-03       Impact factor: 3.685

4.  Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications.

Authors:  A Perry; R B Jenkins; R J Dahl; C A Moertel; B W Scheithauer
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

5.  Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression.

Authors:  M Simon; A von Deimling; J J Larson; R Wellenreuther; P Kaskel; A Waha; R E Warnick; J M Tew; A G Menon
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.

Authors:  D Tabernero; J F San Miguel; M Garcia-Sanz; L Nájera; M García-Isidoro; J A Peréz-Simon; M Gonzalez; J Wiegant; A K Raap; A Orfão
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

7.  Cytogenical analysis of brain tumors by FISH (fluorescence in situ hybridization) and FCM (flow cytometry).

Authors:  H Kasai; K Kawamoto
Journal:  Noshuyo Byori       Date:  1995-03

8.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Authors:  T Visakorpi; E Hyytinen; P Koivisto; M Tanner; R Keinänen; C Palmberg; A Palotie; T Tammela; J Isola; O P Kallioniemi
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

9.  Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma.

Authors:  S W Coons; P C Johnson; J R Shapiro
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

Review 10.  A tiger behind many doors: multiple genetic pathways to malignant glioma.

Authors:  D N Louis; J F Gusella
Journal:  Trends Genet       Date:  1995-10       Impact factor: 11.639

View more
  17 in total

1.  Hyperdiploidy defines a distinct cytogenetic entity of meningiomas.

Authors:  Ralf Ketter; Yoo-Jin Kim; Simone Storck; Jörg Rahnenführer; Bernd F M Romeike; Wolf-Ingo Steudel; Klaus D Zang; Wolfram Henn
Journal:  J Neurooncol       Date:  2007-01-17       Impact factor: 4.130

2.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

3.  Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Abel Castrillo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Ana Belen Nieto; Catarina Resende Oliveira; Maria Celeste Lopes; Alberto Orfao
Journal:  Neuro Oncol       Date:  2010-05-18       Impact factor: 12.300

Review 4.  Diagnostic challenges in meningioma.

Authors:  Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

5.  Intratumor and informatic heterogeneity influence meningioma molecular classification.

Authors:  Abrar Choudhury; Stephanie Hilz; Stephen T Magill; David R Raleigh; Harish N Vasudevan; Javier E Villanueva-Meyer; William C Chen; Calixto-Hope G Lucas; Steve E Braunstein; Nancy Ann Oberheim Bush; Nicholas Butowski; Melike Pekmezci; Michael W McDermott; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2022-06-27       Impact factor: 15.887

6.  Meningioma of the cerebellopontine angle in identical twins: a case report.

Authors:  Shigeo Ohba; Kazunari Yoshida; Yuichi Hirose; Eiji Ikeda; Takeshi Kawase
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

7.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

8.  Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.

Authors:  Angel Maillo; Alberto Orfao; Ana B Espinosa; José María Sayagués; Marta Merino; Pablo Sousa; Monica Lara; María Dolores Tabernero
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

9.  Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas.

Authors:  Gilson S Baia; Stefano Stifani; Edna T Kimura; Michael W McDermott; Russell O Pieper; Anita Lal
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

10.  Association between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer.

Authors:  María González-González; Jacinto Garcia; José A Alcazar; María L Gutiérrez; Luis M Gónzalez; Oscar Bengoechea; María M Abad; Angel Santos-Briz; Oscar Blanco; Manuela Martín; Ana Rodríguez; Manuel Fuentes; Luis Muñoz-Bellvis; Alberto Orfao; Jose M Sayagues
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.